Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.42 |
| ▸ | USP1 | O94782 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661780 | 0.81 | NPC1 (0.52) | PTGS2PTGS1KDM4EALDH1A1HPGD | |
| SCHEMBL25198784 | 0.81 | HTT (0.42) | USP1PTGS2PTGS1NT5E | |
| SCHEMBL31138745 | 0.81 | PTGS2 (0.38) | USP1PTGS2PTGS1 | |
| SCHEMBL31661551 | 0.79 | NPC1 (0.44) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31138587 | 0.79 | KDM4E (0.42) | USP1KDM4EALDH1A1 | |
| SCHEMBL29131089 | 0.79 | KDM4E (0.42) | USP1KDM4EALDH1A1 | |
| SCHEMBL10916369 | 0.79 | PTGS1 (0.57) | USP1PTGS2PTGS1NT5EKDM4E | |
| SCHEMBL28720549 | 0.78 | PTGS2 (0.41) | USP1PTGS2PTGS1 | |
| SCHEMBL29295998 | 0.78 | USP1 (0.44) | USP1PTGS2PTGS1 | |
| SCHEMBL22143054 | 0.77 | USP1 (0.43) | USP1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | AMY1A 1846/4885USP1 1/4885PTGS2 3532/4885 |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | AMY1A 1846/4885USP1 1/4885PTGS2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.